Inventor · disambiguated record
Mira Jung
Also filed as: JUNG MIRA · JUNG MIRA O
14 granted patents·11 pending applications·45 citations·filing 2001–2025
89Inventor score
Files withSHUTTLE PHARMACEUTICALS INC13DRITSCHILO ANATOLY3KOZIKOWSKI ALAN P3UNIV GEORGETOWN3BROWN MILTON L1
Top patents by PatentIndex Score
25 records- 0188US8222451B2Histone deacetylase inhibitors and methods of use thereofKOZIKOWSKI ALAN P·Filed 2010·Granted Jul 17, 2012·9 cites·5 claims
- 0285US8748463B2Histone deacetylase inhibitors and methods of use thereofKOZIKOWSKI ALAN P·Filed 2012·Granted Jun 10, 2014·6 cites·9 claims
- 0385US7842835B2Histone deacetylase inhibitors and methods of use thereofUNIV GEORGETOWN·Filed 2003·Granted Nov 30, 2010·17 cites·11 claims
- 0483US12357650B2Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiationSHUTTLE PHARMACEUTICALS INC·Filed 2023·Granted Jul 15, 2025·0 cites·14 claims
- 0581US9809539B2Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereofSHUTTLE PHARMACEUTICALS LLC·Filed 2015·Granted Nov 7, 2017·4 cites·6 claims
- 0679US8653278B2Isoform selective HDAC inhibitorsKOZIKOWSKI ALAN P·Filed 2007·Granted Feb 18, 2014·5 cites·10 claims
- 0779US8293513B2Histone deacetylase inhibitorsBROWN MILTON L·Filed 2008·Granted Oct 23, 2012·4 cites·21 claims
- 0878US2025302857A1Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With RadiationSHUTTLE PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 0977US2023302034A1Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With RadiationSHUTTLE PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1075US12077515B2Selective histone deacetylase inhibitors for the treatment of human diseaseSHUTTLE PHARMACEUTICALS INC·Filed 2022·Granted Sep 3, 2024·0 cites·20 claims
- 1174US2022055988A1Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereofSHUTTLE PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1269US2020317611A1Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereofSHUTTLE PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1369US2024174630A1Selective histone deacetylase inhibitors for the treatment of human diseaseSHUTTLE PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1468US10730834B2Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereofSHUTTLE PHARMACEUTICALS INC·Filed 2017·Granted Aug 4, 2020·0 cites·10 claims
- 1567US11654157B2Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiationSHUTTLE PHARMACEUTICALS INC·Filed 2018·Granted May 23, 2023·0 cites·10 claims
- 1665US11407723B2Selective histone deacetylase inhibitors for the treatment of human diseaseSHUTTLE PHARMACEUTICALS INC·Filed 2019·Granted Aug 9, 2022·0 cites·5 claims
- 1764US11584733B2Selective histone deacetylase inhibitors for the treatment of human diseaseSHUTTLE PHARMACEUTICALS INC·Filed 2021·Granted Feb 21, 2023·0 cites·20 claims
- 1863US10745352B2Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereofSHUTTLE PHARMACEUTICALS INC·Filed 2016·Granted Aug 18, 2020·0 cites·4 claims
- 1954US2010143242A1Delivery system for therapy comprising hollow seeds, and the method of use thereofDRITSCHILO ANATOLY·Filed 2009·Application pending·0 cites
- 2053US2005222013A1Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapyUNIV GEORGETOWN·Filed 2004·Application pending·0 cites
- 2151US2005287158A1The p65 subunit of nf-kb for the radiosensitization of cellsUNIV GEORGETOWN·Filed 2003·Application pending·0 cites
- 2248US11034667B2Selective histone deacetylase inhibitors for the treatment of human diseaseSHUTTLE PHARMACEUTICALS INC·Filed 2018·Granted Jun 15, 2021·0 cites·6 claims
- 2348US2006173443A1Delivery system for therapy comprising hollow seed, preferably polymericDRITSCHILO ANATOLY·Filed 2006·Application pending·0 cites
- 2448US2006173442A1Delivery system for therapy comprising hollow seed, the method of use thereofDRITSCHILO ANATOLY·Filed 2006·Application pending·0 cites
- 2544US2004067904A1Gene therapy for prostate cancer: sensibilization of cells to dna damaging drugs and radiationFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mira Jung files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →